Simulations Plus today reported results for the 4th quarter and fiscal year 2018. FY18 revenues increased 23%; earnings per share increased 51.4%.
Full Fiscal Year Pharmaceutical Software and Services Revenues Up 22.9%; Earnings per share of $0.50, up 51.4% over prior year
Sprycel® (Dasatinib) is a BCS II weakly basic drug that exhibits strong pH dependent solubility.
It is not currently possible to rapidly estimate the extent of hepatocyte loss during drug‐induced liver injury (DILI). We used a proprietary mechanistic model (DILIsym) to estimate percentage hepatocyte loss due...
This study investigated pharmacokinetics, tissue distribution and excretion of ACT001 in Sprague-Dawley rats. Stability study and metabolism study of ACT001 are conducted.
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of pathophysiology, ranging from hepatic steatosis, through non-alcoholic steatohepatitis (NASH) and hepatic fibrosis, and in rare cases resulting in cirrhosis and liver failure.
Lixivaptan, a vasopressin-2 receptor antagonist, is under development for the treatment of autosomal dominant polycystic kidney disease (ADPKD), an orphan disease with minimal treatment options.
Treatment options for nonalcoholic steatohepatitis (NASH) are limited. One approach targets hepatic acetyl-CoA carboxylase (ACC), which influences de novo lipogenesis (DNL) and fatty acid oxidation.
Regulatory agencies have encouraged the use of mechanistic absorption (MAM) and physiologically-based pharmacokinetic (PBPK) modeling to reduce cost and time to market for new and generic drug products.
Rivaroxaban is an oral anticoagulant which acts by inhibiting factor Xa of the coagulation network.
Conference Call to be on Wednesday, November 14, 2018, at 4:15 PM ET
Quantitative Systems Toxicology (QST) modeling can explain and predict species differences in dose-dependent hepatotoxicity.
RENAsym consortium will use QST to predict and investigate drug-induced kidney injury across various patient groups
This video discusses the enzyme and transporter expression levels that are defined in various tissues, e.g., GI tract, liver, lung, kidney and species (human, dog, monkey, and rat).
Riociguat, a guanyl cyclase inhibitor, is one of its kind drug regimen approved for management of pulmonary arterial hypertension and chronic thromboembolism pulmonary hypertension.
Lixivaptan, a vasopressin-2 receptor antagonist, is being developed for the treatment of autosomal-dominant polycystic kidney disease (ADPKD), an orphan disease that is an unmet medical need.
Bile acid transporter inhibition has been shown to be an important mechanism of drug-induced liver injury (DILI), but the biophase responsible for the transporter inhibition is unclear.
DILIsym Is Used to Predict Bile-Acid Mediated Drug-Induced Liver Injury
A recent bioavailability study raises questions about the universality of the permeability enhancing effect of chitosan on poorly permeable drugs.
In silico pharmacokinetic (PK) simulations are now routinely incorporated into drug development workflows, especially in the later stages.
HTPK lightens the burden of collecting and preparing input variables for full blown PK simulations by using structure-based predictions.
